Current role
John J. Boniface
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Sera Prognostics, Inc. (SERA)
Proxy statement
Current
Company network
Recorded roles and earnings-call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Sera Prognostics, Inc. (SERA) | Chief Scientific Officer | $439,130 | $1,004,192 |
| 2024 | Sera Prognostics, Inc. (SERA) | Chief Scientific Officer | $358,904 | $431,282 |
| 2023 | Sera Prognostics, Inc. (SERA) | Chief Scientific Officer | $398,490 | $871,963 |
| 2022 | Sera Prognostics, Inc. (SERA) | Chief Scientific Officer Represents the aggregate grant date fair value of RSU awards granted in the applicable fiscal year. Grant date fair value is calculated in accordance with Accounting Standards Codification (“ASC”) Topic 718 (“ASC 718”) issued by the Financial Accounting Standards Board (“FASB”). For the assumptions relating to valuations of RSU awards made to our named executive officers, see Note 2 to our audited financial statements, which are included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 20, 2024. Represents the aggregate grant date fair value of option awards granted in the applicable fiscal year. Grant date fair value is calculated in accordance with ASC 718 issued by the FASB. For the assumptions relating to valuations of equity awards made to our named executive officers, see Note 10 to our audited financial statements, which are included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 20, 2024. Consists of bonus payments received under our non-equity incentive compensation plans based upon satisfaction of performance goals. See “Executive Compensation — Non-Equity Incentive Compensation Plan.” For Ms. Lindgardt, other compensation in 2023 consists of 17,473 of fees paid for her service as a non-employee member of our board of directors prior to her appointment as President and Chief Executive Officer on June 8, 2023 and 5,165 of matching contributions made under our 401(k) plan. In 2022, Ms. Lindgardt’s other compensation consists of fees paid for her service as a non-employee member of our board of directors. For Dr. Critchfield, other compensation in 2023 consists of 584,000 of severance pay in accordance with his Retirement and Transition Agreement and 10,025 of continued health insurance coverage. For Mr. Aerts and Dr. Boniface, other compensation consists of matching contributions made under our 401(k) plan. | $406,100 | $826,246 |
Recent activity
No earnings-call appearances or filed executive changes recorded yet.